MARKET WIREYahoo • 3d ago
Vanda Pharmaceuticals Inc. Q3 2026 Earnings Call SummaryMoby summary of Vanda Pharmaceuticals Inc.'s Q3 2026 earnings call
Why VNDA Stock advanced +1.25% Today — RQD Quant Desk Flash
$4.05 +1.25% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.05
Vanda Pharmaceuticals Inc. (VNDA) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $244.9M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.05 (+0.03%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9.4% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VNDA)Realized 20D OHLCV Swing Band: ±11.7%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY VNDA SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)
20D Institutional Volume Accumulation (±11.7% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (35% of score)
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 26.7 (OVERSOLD (<32))
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$4.57-11.8% Next Q
45
Q2 (-2Q)Grade D$4.03-0.5% Next Q
42
Q3 (-1Q)Grade D$4.01+1% Next Q
40
CurrentGrade D-$4.05-8.1% Hist 90D α
37
Trajectory: D (45) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a VNDA Turnaround Squeeze
While VNDA currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.79) and Max Pain ($4.25) forces dealer call-delta covering toward $10.44.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $VNDA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VNDA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why VNDA Stock advanced +1.25% Today — RQD Quant Desk Flash
Vanda Pharmaceuticals Inc. (VNDA) advanced +1.25% to $4.05, trading at 5% of its 52-week range ($3.74 – $9.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($3.74 – $9.94) with RSI-14 at 26.7 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±11.7% around $4.05 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live VNDA Headlines & Catalysts
MARKET WIREBenzinga • 3d ago
12 Health Care Stocks Moving In Thursday's Pre-Market SessionGainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75% to $210.01.
RISK WATCHBenzinga • 3d ago
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on CancerReed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
CATALYSTYahoo • 3d ago
Vanda (VNDA) Q3 2026 Earnings Call TranscriptRevenue surged 24% year over year, driven by Fanapt growth and NEREUS launch momentum.
MARKET WIRESeekingAlpha • 3d ago
Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call TranscriptVanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call October 28, 2026 4:30 PM EDTCompany ParticipantsKevin Moran - Senior VP, CFO & TreasurerMihael...
CATALYSTYahoo • 3d ago
Vanda Pharmaceuticals Q3 Earnings Call HighlightsVanda Pharmaceuticals (NASDAQ:VNDA) reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to specialty-pharmacy
RISK WATCHYahoo • 4d ago
Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue EstimatesVanda (VNDA) delivered earnings and revenue surprises of +48.61% and +5.99%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
RISK WATCHYahoo • 4d ago
Vanda: Q3 Earnings SnapshotWASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $22.
MARKET WIREYahoo • 4d ago
Vanda Pharmaceuticals Reports Third Quarter 2026 Financial ResultsVanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2026.
MARKET WIREBenzinga • 4d ago
Vanda Pharma Q3 2026 Earnings Call TranscriptVanda Pharma (NASDAQ:VNDA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time access to earnings
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring VNDA)
- ✓Walkthrough of VNDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VNDA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -42.96%▼ DESCENDING CHANNEL
2026-10-30O $4.03H $4.11L $3.74C $4.05VOL 1.79M
RES: $4.69SUP: $2.76SMA50: $4.79SMA200: $6.21
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
VNDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +8.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on VNDA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for VNDA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VNDA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VNDA)
Health Care Rank #751 of 1016
⚔️ CAMP vs VNDA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (VNDA vs. CAMP, LFCR, ELDN, EVMN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Vanda Pharmaceuticals Inc. (VNDA) ranks #751 by composite RQD confidence (37/100, grade D-) and #551 by equity capitalization ($244.9M). Within this direct 5-issuer industry benchmark cohort, VNDA leads on earnings valuation at N/A trailing P/E, while VNDA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with VNDA at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| VNDA
ACTIVE
Vanda Pharmaceuticals Inc. | D- | 37/100 | — | — | -35.0% | +1.25% | $244.9M | Benchmark Subject |
| CAMP CAMP4 Therapeutics Corporation | E | 34/100 | — | — | -35.0% | +6.85% | $244.7M | /camp-vs-vnda → |
| LFCR Lifecore Biomedical Inc. | D | 51/100 | — | — | — | +0.15% | $246.8M | /lfcr-vs-vnda → |
| ELDN Eledon Pharmaceuticals Inc. | D | 49/100 | — | — | -35.0% | +10.15% | $247.0M | /eldn-vs-vnda → |
| EVMN Evommune Inc. | D- | 43/100 | — | — | -35.0% | +7.92% | $247.1M | /evmn-vs-vnda → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001347178In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vanda Pharmaceuticals Inc. (VNDA) reported GAAP revenue of $216.1M (+8.7% vs. FY2024 revenue of $198.8M , and +12.2% cumulative change since FY2023) , GAAP net income of -$220.5M, operating cash flow of -$109.4M, and free cash flow of -$110.4M (-579.8% YoY). On the balance sheet, VNDA closed FY2025 with $488.9M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $216.1M | -$220.5M | -$109.4M | -$110.4M | $488.9M | — |
| FY2024 (FY) | 2024-12-31 | $198.8M | -$18.9M | -$15.8M | -$16.2M | $656.2M | — |
| FY2023 (FY) | 2023-12-31 | $192.6M | $2.5M | $12.8M | $12.8M | — | — |
3. VNDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs VNDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $4.05 (+1.25% 1D, market cap $244.9M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, VNDA ranks #751 in composite RQD confidence.
How does VNDA compare to CAMP and LFCR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VNDA carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CAMP (CAMP4 Therapeutics Corporation) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $244.7M) and LFCR (Lifecore Biomedical Inc.) posts a D grade (51/100 RQD, P/E N/A, ROIC —, cap $246.8M). Among the 5-stock peer group, VNDA leads on earnings multiple (N/A) while VNDA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for VNDA?
Per VNDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001347178), Vanda Pharmaceuticals Inc. generated $216.1M in revenue (+8.7% YoY), -$220.5M in net income, and -$110.4M in free cash flow against $488.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is VNDA trading relative to its 50-day, 200-day, and 52-week technical levels?
VNDA last traded at $4.05 (+1.25% on volume of 2,704,250 shares), positioning the stock -15.45% below its 50-day simple moving average ($4.79) and -34.78% below its 200-day simple moving average ($6.21). Across its 52-week range of $3.74 to $9.94, VNDA sits at the 5.0% percentile with a 14-day RSI of 26.7 (OVERSOLD (<32)) and an implied next-earnings move of ±11.7% ($3.58 to $4.52).
VNDA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is VNDA stock moving today?
Why VNDA Stock advanced +1.25% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.